Ks logo

News & Insights

Subscribe
Icon search Icon close

  • People
  • OfficesIcon submenu
    • Icon submenu back back
    • Offices
    • North AmericaIcon submenu
      • Icon submenu back back
      • North America
      • Atlanta
      • Austin
      • Charlotte
      • Chicago
      • Denver
      • Houston
      • Los Angeles
      • Miami
      • New York
      • Northern Virginia
      • San Francisco
      • Silicon Valley
      • Washington, D.C.
    • Europe & Middle EastIcon submenu
      • Icon submenu back back
      • Europe & Middle East
      • Abu Dhabi
      • Brussels
      • Dubai
      • Frankfurt
      • Geneva
      • London
      • Paris
      • Riyadh
    • AsiaIcon submenu
      • Icon submenu back back
      • Asia
      • Singapore
      • Tokyo
  • CapabilitiesIcon submenu
    • Icon submenu back back
    • Capabilities
    • Corporate, Finance and InvestmentsIcon submenu
      • Icon submenu back back
      • Corporate, Finance and Investments
      • Overview
      • Activist Defense
      • Banking and Institutional Finance
      • Capital Markets
      • Construction and Procurement
      • Corporate Governance
      • Emerging Companies and Venture Capital
      • Employee Benefits and Executive Compensation
      • Energy and Infrastructure Projects
      • Financial Restructuring
      • Global Human Capital and Compliance
      • Investment Funds and Asset Management
      • Mergers and Acquisitions (M&A)
      • Middle East and Islamic Finance and Investment
      • Private Credit & Special Situations
      • Private Equity
      • Public Companies
      • Real Estate
      • Structured Finance and Securitization
      • Tax
      • Technology Transactions
    • Government MattersIcon submenu
      • Icon submenu back back
      • Government Matters
      • Overview
      • Antitrust
      • Data, Privacy and Security
      • Environmental, Health and Safety
      • FDA and Life Sciences
      • Government Advocacy and Public Policy
      • Government Contracts
      • Healthcare
      • International Trade
      • National Security and Corporate Espionage
      • Securities Enforcement and Regulation
      • Special Matters and Government Investigations
    • Trial and Global DisputesIcon submenu
      • Icon submenu back back
      • Trial and Global Disputes
      • Overview
      • Antitrust
      • Appellate, Constitutional and Administrative Law
      • Bankruptcy and Insolvency Litigation
      • Class Action Defense
      • Commercial Litigation
      • Construction and Engineering Disputes
      • Corporate and Securities Litigation
      • E-Discovery
      • Intellectual Property
      • International Arbitration and Litigation
      • Labor and Employment
      • Product Liability
      • Professional Liability
      • Toxic & Environmental Torts
    • Industries / IssuesIcon submenu
      • Icon submenu back back
      • Industries / Issues
      • Industries
      • Automotive, Transportation and Mobility
      • Energy
      • Financial Services
      • Food and Beverage
      • Higher Education
      • Life Sciences and Healthcare
      • Technology
      • Issues
      • #MeToo
      • Buy American
      • COVID-19 Vaccine Rollout
      • Crisis Management
      • Environmental Agenda
      • Environmental, Social and Governance (ESG)
      • Focus on Women's Health
      • Russia/Ukraine
      • Special Purpose Acquisition Companies (SPACs)
  • CareersIcon submenu
    • Icon submenu back back
    • Careers
    • LawyersIcon submenu
      • Icon submenu back back
      • Lawyers
      • Experienced Lawyers
    • StudentsIcon submenu
      • Icon submenu back back
      • Students
      • Law Students
      • UK Graduate Recruitment
    • Judicial ClerksIcon submenu
      • Icon submenu back back
      • Judicial Clerks
      • Judicial Clerks
    • Other ProfessionalsIcon submenu
      • Icon submenu back back
      • Other Professionals
      • Other Professionals
  • News & InsightsIcon submenu
    • Icon submenu back back
    • News & Insights
    • NewsIcon submenu
      • Icon submenu back back
      • News
      • Cases & Deals
      • In the News
      • Press Releases
      • Recognitions
    • EventsIcon submenu
      • Icon submenu back back
      • Events
      • Conferences
      • Speaking Engagements
      • Webinars
    • InsightsIcon submenu
      • Icon submenu back back
      • Insights
      • Newsletters
      • Client Alerts
      • Thought Leadership
      • Articles
      • Feature
      • BLOGS
      • COVID-19 Vaccine Updates
      • ESG Excellence
  • AboutIcon submenu
    • Icon submenu back back
    • About
    • Our FirmIcon submenu
      • Icon submenu back back
      • Our Firm
      • History
      • Our Values
    • Diversity & InclusionIcon submenu
      • Icon submenu back back
      • Diversity & Inclusion
      • Overview
      • Women’s Initiatives
      • Racial Diversity
      • LBGTQ+ Affinity
    • CitizenshipIcon submenu
      • Icon submenu back back
      • Citizenship
      • Overview
      • Pro Bono
      • Community Focus
  • Languages

News & Insights

  • NewsIcon submenu
    • Icon submenu back back
    • News
    • Cases & Deals
    • In the News
    • Press Releases
    • Recognitions
  • EventsIcon submenu
    • Icon submenu back back
    • Events
    • Conferences
    • Speaking Engagements
    • Webinars
  • InsightsIcon submenu
    • Icon submenu back back
    • Insights
    • Newsletters
    • Client Alerts
    • Thought Leadership
    • Articles
    • Feature
    • BLOGS
    • COVID-19 Vaccine Updates
    • ESG Excellence
< Back to Bio
Icon close orange Gillian M. Russell

Insights 13 results

Client Alert

January 23, 2023
2022 Year in Review: FDA Drug and Device Advertising and Promotion Enforcement

Article · Source: Chambers and Partners

March 21, 2022
Chambers Global Practice Guide: Pharmaceutical Advertising 2022

Client Alert

August 6, 2021
FDA Finalizes “Intended Use” Regulations

Article · Source: Chambers and Partners

March 19, 2021
Pharmaceutical Advertising

Client Alert

September 24, 2020
FDA Proposes New Rule Modifying its “Intended Use” Regulations

Article · Source: Chambers and Partners

March 2, 2020
Chambers Global Practice Guide: Pharmaceutical Advertising

Client Alert

January 26, 2017
FDA Defends Its First Amendment Position in “Memorandum”

Client Alert

January 20, 2017
FDA Issues Draft Guidance Addressing Communications with Payors

Client Alert

January 19, 2017
FDA Takes Action in the Last Days of the Obama Administration to Clarify Some of Its Views on Off-Label Communications

Article

March 17, 2016
2015 Year in Review: Drug Promotion Warning Letters

Client Alert

March 8, 2016
2015 Year in Review: OPDP and APLB Warning and Untitled Letters

Client Alert

February 10, 2015
FDA Revises Approach to Presentation of Risk Information in Brief Summary

© 2023 King & Spalding LLP
  • Contact Us
  • Disclaimer
  • Privacy Notice
  • Transparency Disclosure
  • Cookie Policy
  • Copyright Notice
  • Regulatory Notices
  • CPRA Privacy Notice
  • K&S Alumni Group